Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa Bay news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Charlotte news in your inbox

Catch up on the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Multiple promising vaccines for the coronavirus are in development, Peter Marks, the director of the Food and Drug Administration’s biologics center, said during an Axios virtual event Monday.

What he's saying: Marks said the vaccine will meet the FDA's high standards of efficacy and safety, while accelerating the approval process to combat for a vaccine.

What they're saying: Marks said he hopes a vaccine would be available within nine months, rather than the usual 12-18 months the process normally takes.

  • “The hope is that by working with those [promising candidates] in a way that we haven’t done things exactly the same way in the past, will move the vaccine development forward in a way that could lead to a vaccine in maybe nine months instead of the 12-18 months that people have talked about," Marks said.

Our thought bubble: Axios' Bob Herman pointed out during the event that most experts say that nine months is optimistic to develop a vaccine, because it's never happened before.

Editor's note: This story has been updated to clarify that Marks hopes, not predicts, that a vaccine will be available within nine months.

Go deeper

Aug 12, 2020 - Health

Fauci says he "seriously" doubts Russia's coronavirus vaccine is safe

NIAID director Anthony Fauci testifies during a July congressional hearing on Capitol Hill. Photo: Kevin DietschI/AFP via Getty Images

NIAID director Anthony Fauci cast doubt during a National Geographic discussion due to air this week on the effectiveness of Russia's registered coronavirus vaccine touted by President Vladimir Putin on Tuesday.

Why it matters: "Having a vaccine ... and proving that a vaccine is safe and effective are two different things," Fauci told told ABC News' Deborah Roberts in the discussion, expected to air on Thursday. His comments add to the weight of skepticism from scientists around the world on the Russia vaccine. There is no published scientific to support support Putin's claims.

Aug 11, 2020 - Podcasts

Russia’s vaccine gamble

Russia announced Tuesday that it approved a vaccine for COVID-19 and has plans to inoculate health care workers, teachers and others in the coming months, despite barely starting Phase 3 clinical trials.

Axios Re:Cap digs into the ramifications of this announcement for the global vaccine race with Derek Lowe, medicinal chemist, author and expert on drug development and the pharmaceutical industry.

Aug 11, 2020 - Health

Trump administration buys 100 million doses of Moderna's vaccine

A volunteer in Moderna's vaccine clinical trial receives a shot. Photo: Paul Hennessy/NurPhoto via Getty Images

The U.S. government has agreed to buy 100 million doses of Moderna's experimental coronavirus vaccine for $1.5 billion, or $15 per dose.

Why it matters: The Trump administration, through Operation Warp Speed, has now bought initial batches of vaccines from Moderna, GlaxoSmithKline and Sanofi, Pfizer, Novavax, Johnson & Johnson and AstraZeneca before knowing whether they are safe and effective. The federal government also appears to own some of the patent rights associated with Moderna's vaccine.